Enlivex Therapeutics (ENLV), which is listed on the Nasdaq and the Tel Aviv Stock Exchange, continues to trade without any interruption. Due to a technical error, TipRanks mistakenly reported that the company, which develops a drug pipeline for the treatment of autoimmune and inflammatory conditions, had suspended trading. TipRanks unequivocally retracts that erroneous report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Enlivex stock rose by .96% in Friday’s trading, and has traded sideways for the past three months. The company met earnings estimates in its past two reports.
